Schwab Charles Investment Management Inc. trimmed its position in Natus Medical Inc (NASDAQ:BABY) by 7.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,741 shares of the medical equipment provider’s stock after selling 12,821 shares during the period. Schwab Charles Investment Management Inc. owned about 0.48% of Natus Medical worth $5,721,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Natus Medical in the 3rd quarter valued at about $138,000. Sei Investments Co. lifted its holdings in Natus Medical by 149.9% in the 3rd quarter. Sei Investments Co. now owns 7,952 shares of the medical equipment provider’s stock valued at $298,000 after purchasing an additional 4,770 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in Natus Medical in the 3rd quarter valued at about $315,000. Capital Management Associates NY purchased a new position in Natus Medical in the 3rd quarter valued at about $412,000. Finally, Municipal Employees Retirement System of Michigan lifted its holdings in Natus Medical by 60.1% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 12,420 shares of the medical equipment provider’s stock valued at $466,000 after purchasing an additional 4,660 shares in the last quarter. Institutional investors own 95.81% of the company’s stock.
In other news, Director Ken Ludlum sold 4,000 shares of the stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $31.68, for a total transaction of $126,720.00. Following the transaction, the director now directly owns 93,825 shares in the company, valued at approximately $2,972,376. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.50% of the company’s stock.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.12). The company had revenue of $131.40 million for the quarter, compared to analysts’ expectations of $131.38 million. Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The company’s revenue was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.51 earnings per share. research analysts anticipate that Natus Medical Inc will post 1.63 earnings per share for the current year.
Natus Medical declared that its board has approved a stock buyback plan on Thursday, February 22nd that allows the company to repurchase $30.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.
BABY has been the topic of several recent analyst reports. BidaskClub lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Zacks Investment Research lowered shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. William Blair lowered shares of Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Benchmark reiterated a “buy” rating and set a $49.00 price objective (down from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. Finally, Roth Capital set a $39.00 price objective on shares of Natus Medical and gave the stock a “buy” rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. Natus Medical presently has a consensus rating of “Hold” and a consensus price target of $44.33.
TRADEMARK VIOLATION NOTICE: “Schwab Charles Investment Management Inc. Sells 12,821 Shares of Natus Medical Inc (BABY)” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/14/schwab-charles-investment-management-inc-sells-12821-shares-of-natus-medical-inc-baby.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.